Last reviewed · How we verify
Ibrutinib (Maintenance)
Ibrutinib is a Bruton's tyrosine kinase (BTK) inhibitor that blocks BTK signaling in B cells and other immune cells, reducing their proliferation and survival.
Ibrutinib is a Bruton's tyrosine kinase (BTK) inhibitor that blocks BTK signaling in B cells and other immune cells, reducing their proliferation and survival. Used for Chronic lymphocytic leukemia (CLL) — maintenance therapy, Mantle cell lymphoma (MCL) — maintenance therapy, Waldenstrom macroglobulinemia — maintenance therapy.
At a glance
| Generic name | Ibrutinib (Maintenance) |
|---|---|
| Also known as | Imbruvica |
| Sponsor | Prof. Dr. M. Dreyling (co-chairman) |
| Drug class | Bruton's tyrosine kinase (BTK) inhibitor |
| Target | BTK (Bruton's tyrosine kinase) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Ibrutinib covalently binds to BTK, a key enzyme in the B-cell receptor signaling pathway. By inhibiting BTK, it prevents B-cell activation, proliferation, and migration, leading to reduced tumor cell survival in B-cell malignancies. In maintenance therapy, continued BTK inhibition helps prevent disease relapse and progression.
Approved indications
- Chronic lymphocytic leukemia (CLL) — maintenance therapy
- Mantle cell lymphoma (MCL) — maintenance therapy
- Waldenstrom macroglobulinemia — maintenance therapy
Common side effects
- Diarrhea
- Fatigue
- Nausea
- Bruising/bleeding
- Infection
- Atrial fibrillation
- Rash
Key clinical trials
- Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma (PHASE3)
- Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma (PHASE2)
- MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas (PHASE2)
- Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With RR CLL (PHASE2)
- Ibrutinib + R-CHOP Followed by Ibrutinib Maintenance (PHASE2)
- Efficacy of First Line B-RI for Treatment Naive Waldenström's Macroglobulinemia (PHASE2)
- A Trial of Obinutuzumab,GDC-0199 Plus Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma Patients (PHASE1, PHASE2)
- Ofatumumab & Ibrutinib + Allogeneic Bone Marrow Transplant or Consolidation in High Risk Chronic Lymphocytic Leukemia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |